Benzinga | Mar 2, 2021 07:10AM EST

SVB Leerink Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $126

SVB Leerink analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $125 to $126.